Assessment of the impact of the use of durvalumab for the treatment of advanced small cell lung cancer on the achievement of the target "reduction in mortality from neoplasms"

Abstract

Aim. Impact evaluation of effective methods for advanced small cell lung cancer treatment using the drug durvalumab on the achievement of the Russian Federation national and regional programs Healthcare Development target indicator reduction of mortality from neoplasms. Materials and methods. The methodology of this study is based on general scientific research methods: general logical (analysis, synthesis, induction), theoretical (generalization), empirical (description, calculation, measurement, comparison). The regulatory framework of the research work was made up by the legislation of the Russian Federation, documents regulating the procedure for providing medical care to patients with malignant neoplasms, technical regulation norms enshrined in the documents of the national standardization system that regulate the procedure for health technologies assessment. As an empirical base, the available official data on the epidemiology of lung cancer, Russian and foreign scientific publications, Russian clinical guidelines for the diagnosis and treatment of malignant neoplasms of lungs were analyzed. To conduct health technologies assessment, a mathematical model was developed based on Microsoft Excel 2019 software. The mathematical apparatus used to create a predictive model adapted to predict the results of healthcare cancer programs at the federal and regional levels. Results. The use of durvalumab for the treatment of advanced small cell lung cancer will provide an increase in the achievement of the target indicator reduction of mortality from neoplasms of the national program Healthcare Development in 2022 by 21.3% (499 additionally prevented deaths), in 2023 by 7.0% (366 additionally averted deaths), in 2024 by 6.0% (441 additionally averted deaths). Obtained results show that the use of durvalumab in combination with standard chemotherapy in patients with advanced small cell lung cancer can have a significant impact on the achievement of targets set in healthcare cancer programs. Conclusion. The durvalumab usage in real practice in combination with standard chemotherapy (etoposide + platinum drug), in comparison with the use of only standard chemotherapy (etoposide + platinum drug), will reduce cancer mortality and will contribute to achieving the targets of the Russian Federation national and regional programs Healthcare Development reduction of mortality from neoplasms.

Keywords

• neoplasms mortality
• lung cancer
• durvalumab
• national program “healthcare development“